EUCTR2011-006140-78-ES进行中（未招募）1 期
International, multicenter, open-label, treatment-extension study for subjects who completed a Phase 1 or Phase 2 parental study to continue receiving treatment withSAR245408 or SAR245409 as a monotherapy or as a combination regimen.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •I 01. Males or females enrolled in Phase 1 or Phase 2 studies of SAR245408 or SAR245409 as monotherapy or in combination with other regimens who have
- •complete data collection for the primary endpoint(s) of the parental study or who are being treated beyond the parental study cut-off.
- •I 02. All sexually active subjects (male and female) must agree to continue to use accepted methods of barrier contraception (ie, condoms) during the course
- •of the study and for 3 months after discontinuation of study treatment. For women of childbearing potential and for men who can father a child, a second
- •method of contraception in addition to a barrier method is recommended.
- •Hormonal contraception should be avoided in subjects taking SAR245408 due to possible drug-drug interaction.
- •I 03. Female subjects of childbearing potential must have a negative pregnancy test at baseline. Females of childbearing potential are defined as sexually mature women without prior hysterectomy or who have had any evidence of menses in the past 12 months. However, women who have been amenorrheic
- •for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to other causes, including prior chemotherapy, antiestrogens, or ovarian suppression
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 130
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •E 01. The subject discontinued the parental study due to toxicity.
- •E 02. Ongoing Grade 3 or higher Adverse Event (AE).
- •E 03. Ongoing Serious Adverse Event (SAE).
- •E 04. Ongoing dose interruption for any reason.
- •E 05. The subject has inadequate organ and marrow function as follows
- •- Absolute neutrophil count (ANC): <1500/mm3 (solid tumor patients) or <1000/mm3 (lymphoma patients)
- •- Platelets: <100,000/mm3 (solid tumor patients) or <30,000/mm3 (lymphoma patients)
- •- Hemoglobin: <9 g/dL (solid tumor patients) or <8 g/dL (lymphoma patients)
- •- Bilirubin: >1.5 mg/dL (>2.0 mg/dL for patients with Gilbert?s syndrome)
- •- Serum creatinine: >1.5 times the upper limit of normal (1.5 x ULN) (or calculated creatinine clearance: <60 mL/min) for solid tumor patients or >1.5 x
- •ULN (or calculated creatinine clearance: <40 mL/min) for lymphoma patients
- •- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST): >1.5 x ULN
- •- Fasting plasma glucose (FPG): ?160 mg/dL
- •- Prothrombin time/international normalized ratio (PT/INR) and activated partial thromboplastin time (aPTT) >1.5 × ULN
- •E 06. The subject has a baseline corrected QT interval (QTc) >470 ms.
- •E 07. The subject has a known allergy or hypersensitivity to components of the study treatment formulation(s).
- •E 08. The subject is pregnant or breastfeeding
研究者
相似试验
进行中（未招募）
1 期
Open label treatment extension study with SAR245408 or SAR245409 as a monotherapy or as a combination regimeeoplasm malignantMedDRA version: 14.1Level: PTClassification code 10028997Term: Neoplasm malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-006140-78-FRSanofi-aventis recherche & développement150
进行中（未招募）
不适用
Open label treatment extension study with SAR245408 or SAR245409 as a monotherapy or as a combination regimeeoplasm malignantMedDRA version: 17.0Level: PTClassification code 10028997Term: Neoplasm malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-006140-78-BESanofi-aventis recherche & développement150
进行中（未招募）
1 期
International treatment-extension study in adult participants with multiple myeloma and who have derived clinical benefit from isatuximabMultiple myelomaEUCTR2022-002253-26-FRSanofi-aventis recherche & développement70
招募中
1 期
International treatment-extension study in adult participants with multiple myeloma and who have derived clinical benefit from isatuximabMedDRA version: 21.1Level: PTClassification code 10035226Term: Plasma cell myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Multiple myelomaEUCTR2022-002253-26-DESanofi-aventis recherche & développement70
招募中
2 期
International treatment-extension study in adult participants with multiple myeloma and who have derived clinical benefit from isatuximabCancer2023-507180-19-00Sanofi-Aventis Recherche & Developpement37